[This article was first published in Army Sustainment Professional Bulletin, which was then called Army Logistician, volume 2, number 5 (September–October 1970), pages 12–13. The text is ...

InflaRx (NASDAQ:IFRX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.27) ...

One factor that seems to be involved is C5a, a protein involved in chemotaxis. Theoretically, blocking C5a receptor (C5aR) activity could form a therapeutic strategy for RA. The recently developed ...

Multiple analyses also showed vilobelimab can promote significant and sustained reductions in C5a, which is a key mediator of the inflammatory cascade. We believe that the C5a/C5aR pathway remains ...

N.V. announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum and ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which targets the biological activity of C5a and demonstrates high selectivity towards its target in human blood.